The Firm is representing Daiichi Sankyo in connection with its proposed acquisition of Plexxikon Inc. for an initial purchase price of $805 million. Additional potential payments totaling approximately $130 million will be made upon the achievement of certain milestones associated with the approval of PLX 4032, a late-stage oncology product.
Plexxikon Inc., a pharmaceutical company based in Berkeley, California, is a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease. Daiichi Sankyo is a Japan-based global pharmaceutical company.
The Simpson Thacher team for this transaction included Gary Horowitz, Ellen Rosenberg, Maura Whelan and Scott Naturman (M&A); Noah Leibowitz and Alexander Key (Intellectual Property); Steve Todrys and Jason Vollbracht (Tax); Tristan Brown (Executive Compensation and Employee Benefits); and Ken Ehrhard (Antitrust).
